So your point is - analysts are unhappy because the time it is...

So your point is - analysts are unhappy because the time it is taking to get to the market for zircaix and pixclara?

This isn’t a good reason to attribute some value for future expected cash flows imo

imo there being lazy

Im not an analyst but if I was, I’d be looking at NCCN guidelines to determine market sizes and opportunities, label expansions, ex USA markets and their opportunities etc. which I have my own mud map of.

I haven’t seen them do any of that. They’re analyzing data as it’s released to the market. No speculation or skill
there.

I personally step it in 3 likely scenarios based on the current pipeline.

But hey, I’m an engineer. Not a scientist or stock analyst.